Placeholder Banner

ICH: BIO Submits Comments on S11 Nonclinical Safety Testing in Support of Development of Pediatric Medicines

April 1, 2019

BIO submitted comments to the Food and Drug Administration (FDA) on the draft guidance, S11 Nonclinical Safety Testing in Support of Development of Pediatric Medicines.

BIO's comments address the use of datasets, in vitro nonclinical investigations, and the necessity of repeating juvenile toxicity studies on a prodrug of an approved drug when there may or may not be existing adult toxicity data for the prodrug.

Download Full Comments Below
BIO Comments On S11 Nonclinical Safety Testing In Support Of Development Of Pediatric Medicines FDA-2018-D-4524
Read full comment letter below
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
The Biotechnology Innovation Organization (“BIO”) would like to submit the following comments regarding FDA’s recent proposal to implement aspects of the Canadian importation provisions of Section 804 of the Food Drug & Cosmetics Act (“FD&C…